Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.42) by 7.14 percent. This is a 28.57 percent decrease over losses of $(0.35) per share from the same period last year.